| 5.37 0.004 (0.07%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.34 | 1-year : | 8.44 |
| Resists | First : | 6.29 | Second : | 7.23 |
| Pivot price | 5.74  |
|||
| Supports | First : | 4.76 | Second : | 3.96 |
| MAs | MA(5) : | 5.29 |
MA(20) : | 5.75 |
| MA(100) : | 4.81 |
MA(250) : | 3.22 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.6 |
D(3) : | 22.8 |
| RSI | RSI(14): 45.7 |
|||
| 52-week | High : | 8.04 | Low : | 1.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ QTTB ] has closed above bottom band by 33.1%. Bollinger Bands are 34.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.48 - 5.51 | 5.51 - 5.53 |
| Low: | 5.2 - 5.24 | 5.24 - 5.27 |
| Close: | 5.31 - 5.37 | 5.37 - 5.42 |
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
Sun, 10 May 2026
Number of shareholders of Q32 Bio Inc. – NASDAQ:QTTB - TradingView
Sat, 09 May 2026
Q32 Bio gears up to report Q1 earnings: What's in the cards? - MSN
Fri, 08 May 2026
Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade - Zacks Investment Research
Wed, 06 May 2026
Q32 Bio: Q1 Earnings Snapshot - theheraldreview.com
Tue, 05 May 2026
Q32 Bio: Q1 Earnings Snapshot - KVUE
Tue, 05 May 2026
Q32 targets mid-2026 hair-loss data after first extension dose - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 61.7 (%) |
| Shares Short | 382 (K) |
| Shares Short P.Month | 351 (K) |
| EPS | 2.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.26 |
| Profit Margin | 55.4 % |
| Operating Margin | 85.3 % |
| Return on Assets (ttm) | 13.7 % |
| Return on Equity (ttm) | 125 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 2.03 |
| Sales Per Share | 3.16 |
| EBITDA (p.s.) | 1.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | 2.21 |
| PEG Ratio | 0 |
| Price to Book value | 1.64 |
| Price to Sales | 1.69 |
| Price to Cash Flow | -2.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|